A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 11 Oct 2019 Planned End Date changed from 1 Nov 2021 to 6 Dec 2021.
- 11 Oct 2019 Planned primary completion date changed from 1 Nov 2021 to 6 Dec 2021.
- 08 Aug 2019 Planned End Date changed from 22 Nov 2021 to 1 Nov 2021.